Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 115

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9B
Chunk 115
---
31, 2024, deferred
offering costs from December 31, 2023 of $303,281 and offering costs of $863,744 incurred in 2024 were charged against additional paid
in capital.

    F-13

Telomir
                                            Pharmaceuticals, Inc.

notes
to the financial statements

DECEMBER
31, 2024 and  2023

Warrants

In
connection with various transactions and the IPO summarized below, the Company issue stock warrants. Warrant activity for the year ended
December 31, 2024 is summarized below:

Schedule
of warrant activity

    Weighted  

    Weighted  
    Average  

    Number of  
     Average
 Exercise  
    Remaining
 Contractual  
    Aggregate 

     Warrants  
     Price  
    Term (Years)  
    Intrinsic Value 
  
    Balance Outstanding as January 1, 2023 
     -  
    $-  
     -  
     - 
  
    Granted 
     2,774,057  
    $4.85  
     5.0 (1) 
             - 
  
    Balance Outstanding as December 31, 2023 
     2,774,057  
    $4.85  
     4.5 (1) 
     - 
  
    Granted 
     50,000  
    $7.00  
     3.2  
     - 
  
    Exercised 
     (10,000) 
    $3.73  
     -  
     - 
  
    Balance Outstanding as December 31, 2024 
     2,814,057  
    $4.97  
     3.49 (2) 
     - 
  
    Exercisable, December 31, 2024 
     2,814,057  
    $4.97  
     3.49 (2) 
     - 

(1)The
warrants herein consist of various contractual terms. The warrants herein consist of 2,439,025
warrants issued to Bay Shore
Trust that have a remaining contractual term of 4.5
years as of December 31, 2023,
and 335,032
warrants issued to investors
associated